CoChat

Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)

Open access
Simpson, Eric L., Forman, Seth, Silverberg, Jonathan I., Zirwas, Matthew, Maverakis, Emanual, Han, George, Guttman-Yassky, Emma, Marnell, Daniel, Bissonnette, Robert, Waibel, Jill, Nunes, Fabio P., DeLozier, Amy M., Angle, Robinette, Gamalo, Margaret, Holzwarth, Katrin, Goldblum, Orin, Zhong, Jinglin, Janes, Jonathan, Papp, Kim · 2021 · Journal of the American Academy of Dermatology
Cited by 140

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

BACKGROUND Baricitinib, an oral, selective Janus kinase (JAK)1/JAK2 inhibitor, is being studied for moderate-to-severe atopic dermatitis (AD) in adults. OBJECTIVE To evaluate the efficacy and safety of baricitinib monotherapy in a North American Phase 3 trial (BREEZE-AD5/NCT03435081) of adults with moderate-to-severe AD who responded inadequately or were intolerant to topical therapy. METHODS Patients (N=440) were randomized 1:1:1 to once-daily placebo or baricitinib (1 mg or 2 mg). The primary endpoint was the proportion of patients achieving ≥75% reduction in the Eczema Area and Severity Index (EASI75) at Week 16. A key secondary endpoint was the proportion of patients achieving a validated Investigator Global Assessment for AD (vIGA-AD™) score of 0 (clear)/1(almost clear) with ≥2-point improvement. RESULTS At Week 16, the proportion of patients achieving EASI75 was 8%, 13%, and 30% (P <.001, 2 mg vs. placebo) and those with a vIGA-AD 0/1 were 5%, 13%, and 24% (P <.001, 2 mg vs. placebo), for placebo, baricitinib 1 mg, and 2 mg, respectively. Safety findings were similar to other baricitinib AD studies. LIMITATIONS Short-term clinical trial results may not be generalizable to real-world settings. CONCLUSION Baricitinib was efficacious for patients with moderate-to-severe AD with no new safety findings over 16 weeks.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaad.2021.02.028

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 140

Metadata

Authors
Simpson, E. L., Forman, S., Silverberg, J. I., Zirwas, M., Maverakis, E., Han, G., Guttman-Yassky, E., Marnell, D., Bissonnette, R., Waibel, J., Nunes, F. P., DeLozier, A. M., Angle, R., Gamalo, M., Holzwarth, K., Goldblum, O., Zhong, J., Janes, J., & Papp, K.
Venue
Journal of the American Academy of Dermatology
Publisher
Elsevier BV
Published
2021-07
Volume
85
Issue
1
Pages
62-70
ISSN
0190-9622 (ISSN-L)
OpenAlex
W3129325639
Cited by
140
References
1
FWCI
19.82
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). https://app.cochat.ai/papers/10.1016/j.jaad.2021.02.028
The paper
Simpson, E. L., Forman, S., Silverberg, J. I., Zirwas, M., Maverakis, E., Han, G., Guttman-Yassky, E., Marnell, D., Bissonnette, R., Waibel, J., Nunes, F. P., DeLozier, A. M., Angle, R., Gamalo, M., Holzwarth, K., Goldblum, O., Zhong, J., Janes, J., & Papp, K. (2021). Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2021.02.028

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.